Speaker(s): 

Jeff Hosry, MD, Staff Member, Geisinger - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Identify the use of Maribavir in the treatment of CMV infection post HCT

2. Review the safety of Maribavir in the treatment of CMV infection post HCT

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Stanley Martin, MD; Julie Gombert, RN; Bradley Lauver, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.